FY2026 Earnings Estimate for Neogen Issued By Zacks Research

Key Points

• Zacks Research raised its FY2026 EPS estimate for Neogen to $0.22 (from $0.20) but also cut multiple near‑term estimates and lowered FY2027/FY2028 forecasts (FY2028 from $0.37 to $0.28), indicating a mixed near‑term outlook.
• Neogen beat the quarter with $0.09 EPS vs. $0.04 expected and revenue of $211.2M vs. $204.6M expected, though revenue was down 4.4% year‑over‑year and the company reported a deeply negative net margin (~69.9%).
• Analyst consensus is a "Hold" with a $10.67 target, the stock trades around $9.09 (market cap ~$1.98B), and institutional investors own roughly 96.7% of shares.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Equities researchers at Zacks Research upped their FY2026 EPS estimates for Neogen in a research note issued to investors on Thursday, April 30th. Zacks Research analyst Team now forecasts that the company will earn $0.22 per share for the year, up from their prior estimate of $0.20. The consensus estimate for Neogen's current full-year earnings is $0.22 per share. Zacks Research also issued estimates for Neogen's Q1 2027 earnings at $0.04 EPS, Q3 2027 earnings at $0.05 EPS, Q4 2027 earnings at $0.06 EPS, FY2027 earnings at $0.21 EPS, Q1 2028 earnings at $0.06 EPS, Q2 2028 earnings at $0.08 EPS, Q3 2028 earnings at $0.06 EPS and FY2028 earnings at $0.28 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last released its quarterly earnings data on Thursday, April 9th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. Neogen had a positive return on equity of 2.35% and a negative net margin of 69.93%.The firm had revenue of $211.20 million for the quarter, compared to the consensus estimate of $204.62 million. The company's quarterly revenue was down 4.4% compared to the same quarter last year.

Several other analysts also recently issued reports on NEOG. Guggenheim reaffirmed a "buy" rating and set a $12.00 price objective (up from $8.00) on shares of Neogen in a report on Friday, January 9th. Wall Street Zen cut Neogen from a "buy" rating to a "hold" rating in a research report on Saturday, April 11th. William Blair reissued a "market perform" rating on shares of Neogen in a report on Monday, March 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Neogen in a research report on Friday, April 10th. Finally, Piper Sandler restated a "neutral" rating and set a $10.00 price target (up from $6.50) on shares of Neogen in a research note on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Neogen currently has a consensus rating of "Hold" and a consensus target price of $10.67.

Neogen Price Performance

NASDAQ NEOG opened at $9.09 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.92 and a quick ratio of 2.84. The firm has a market cap of $1.98 billion, a P/E ratio of -3.25, a price-to-earnings-growth ratio of 4.33 and a beta of 1.84. The stock's 50-day moving average is $9.70 and its two-hundred day moving average is $8.40. Neogen has a fifty-two week low of $4.53 and a fifty-two week high of $11.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of Neogen by 84.9% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 351,155 shares of the company's stock valued at $2,005,000 after acquiring an additional 161,241 shares during the period. ING Groep NV bought a new stake in shares of Neogen in the 3rd quarter worth about $80,288,000. Public Sector Pension Investment Board increased its position in shares of Neogen by 26.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 847,266 shares of the company's stock worth $4,838,000 after purchasing an additional 174,962 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Neogen during the 3rd quarter worth about $28,550,000. Finally, CIBC Bancorp USA Inc. bought a new position in Neogen during the 3rd quarter valued at about $28,969,000. Institutional investors own 96.73% of the company's stock.

Key Headlines Impacting Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Zacks raised FY2026 EPS to $0.22 (from $0.20), and nudged Q4 2027 up to $0.06, signaling at least one nearer‑term improvement in expectations that could be supportive if results follow through.
• Neutral Sentiment: Ameresco announced formation of a Neogenyx biogas joint venture with HASI — the item references “Neogenyx” but does not indicate direct operational or financial involvement by Neogen Corporation, so its impact on NEOG is unclear. Article Title
• Negative Sentiment: Zacks cut multiple near‑term EPS estimates across Q1–Q3 2027 and Q1–Q3 2028 and lowered FY2027 and FY2028 forecasts substantially (FY2028 from $0.37 to $0.28). Those downward revisions reduce near‑term earnings visibility and likely explain selling pressure. Additionally, market headlines noting that “Neogen and Baxter shares are falling” highlight momentum selling and negative sentiment. Article Title

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.